NEWER DRUGS FOR THE TREATMENT OF DEPRESSION AND ANXIETY

NEWER DRUGS

TREATMENTS FOR DEPRESSION AND ANXIETY

Drug Name	Pharmacologic Action	Company	Indication	Developmental Phase
Vilazodone	5-HT1A partial agonist, serotonin reuptake inhibitor	Clinical Data Online, Inc.	Depression	NDA anticipated in late 2009
Valdoxan (agomelatine, AGO 178)	5-HT2C antagonist, 5-HT2B antagonist, melatonin M1/M2 receptor agonist	Servier, Novartis	Depression, anxiety	US: Phase III; EU: available as of mid-2009
Lu AA21004	5-HT3 antagonist, 5-HT1A partial agonist	Lundbeck	Depression, anxiety	Phase III (results not expected until 2011)
LY2216684	Norepinephrine reuptake inhibitor	Eli Lilly	Depression, ADHD	Phase III
SEP-227162	DA/NE/5-HT reuptake inhibitor	Sepracor	Depression, anxiety	Phase III
F2695, levomilnacipran	enantiomer of milnacipran	Forest Labs, Pierre Fabre	Depression	Phase II
Lu AA24530	5-HT3 and 5-HT2C antagonist, serotonin reuptake inhibitor	Lundbeck	Depression, anxiety	Phase II
SEP-225289	DA/NE/5-HT reuptake inhibitor	Sepracor	Depression, anxiety	Phase II
Losmapimod, GSK 856553	P38 kinase inhibitor	GSK	Depression	Phase II
GW823296 (orvepitant)	NK1 antagonist	GSK	Depression, anxiety	Phase II
AZD6765	NMDA antagonist	AstraZeneca	Depression, anxiety	Phase II
TC-5214	Nonselective Nicotinic acetylcholine receptor antagonist	Targacept	Depression	Phase II
ONO-2333Ms	CRF1 antagonist	Ono Pharmaceuticals	Depression, anxiety	Phase II
Nemifitide (INN 00835)	Pentapeptide analog of melanocyte-inhibiting factor (MIF-1) administered intravenously (mechanism unknown)	Tetragenex	Depression	Phase II
SSR 411298	FAAH (fatty acid amide hydrolase) inhibitor	Sanofi-Aventis	Depression (in the elderly)	Phase II
ORG 26576	AMPA receptor modulator	Schering-Plough	Depression	Phase II
TIK-101/d-cycloserine	NMDA anatagonist	Tikvah Pharmaceuticals	Anxiety, OCD	Phase II
ORG 34517/34850	Glucocorticoid receptor type II (GRII) antagonist	Schering-Plough	Depression, psychosis	Phase II
GSK561679	CRF1 antagonist	GSK	Depression (in wom	Phase II
Tyrima™, CX157	Reversible monoamine oxidase A (MAO-A) inhibitor	CeNeRx	Depression, anxiety	Phase II
RO4917523, EVT101	NMDA antagonist	Evotec, Roche	Depression	Phase II
GSK 588045	5-HT1 antagonist	GSK	Depression, anxiety	Phase II
RX-10100	Unknown serotonin and dopamine modulator	Rexahn	Depression	Phase II
AZD7325	GABA receptor partial agonist	AstraZeneca	Anxiety	Phase II
AZD2327	Enkephalinergic modulator	AstraZeneca	Anxiety	Phase II
SA4503	Sigma receptor agonist	Eisai, M's Science	Depression, post-stroke recovery	Phase II (Europe)
PRE703	MgluR agonist	Prescient	Anxiety	Phase I
JNJ-19567470, TS-041	CRF1 antagonist	Janssen (Johnson & Johnson), Taisho	Depression, anxiety	Phase I
SSR 125543	CRF1 antagonist	Sanofi-Aventis	Depression, anxiety, hyperphagia	Phase I
GSK 163090	5-HT1 antagonist	GSK	Depression, anxiety	Phase I
TC-2216	Nicotinic acetylcholine receptor (alpha4beta2) antagonist	Targacept	Depression	Phase I
URB597	FAAH (fatty acid amide hydrolase) inhibitor	Schering-Plough	Depression	Phase I
AZD6280	GABA receptor partial agonist	AstraZeneca	Anxiety	Phase I

TREATMENTS FOR SLEEP DISORDERS

Drug Name	Pharmacologic Action	Company	Indication	Developmental Phase
Ciltyri®, Eplivanserin, SR 46349	5-HT2A receptor antagonist	Sanofi-Aventis	Sleep disorders	US/EU decisions expected in 4th quarter 2009
ORG 50081 (esmirtazapine)	5-HT2 antagonist, H1 antagonist, alpha-2-adrenoceptor antagonist	Schering-Plough	Sleep disorders, hot flashes	Phase III
Tasimelte, VEC-162	Melatonin receptor agonist	Vanda Pharmaceuticals	Sleep disorders, depression	Phase III
Almorexant, ACT-078573	Orexen OX1 and OX2 receptor antagonist	Actelion	Sleep disorders	Phase III
PD-6735	Melatonin receptor agonist	Phase 2 Discovery	Sleep Disorders	Phase II
Pimavanserin, ACP-103	Serotonin 5-HT2A receptor inverse agonist, dopamine D2/D3 receptor partial agonist, acetylcholine M1 receptor agonist	Acadia	Sleep disorders, Parkinson's disease psychosis, schizophrenia co-therapy	Phase II
PD-200,390	Voltage-gated calcium channel alpha(2)delta subunit modulator	Pfizer	Sleep disorders	Phase II
EVT 201	GABA-A partial agonist	Evotec	Sleep disorders	Phase II
LY2624803, HY10275	5-HT2A and histamine H1 receptor antagonist	Eli Lilly, Hypnion	Depression, ADHD	Phase II
TIK-301, LY156735	Melatonin agonist, 5-HT2B/5-HT2C antagonist	Tikvah Pharmaceuticals	Sleep disorders	Phase II

TREATMENTS FOR PSYCHOSIS/BIPOLAR DISORDER

Drug Name	Pharmacologic Action	Company	Indication	Developmental Phase
Fanapt ® (iloperidone)	5-HT2A antagonist, D2/D3 antagonist, alpha-1-adrenoceptor antagonist	Vanda Pharmaceuticals	Psychosis	Approved 5/6/09
Saphris™ (asenapine, ORG 5222)	5-HT2 antagonist, D2 partial agonist	Schering-Plough	Psychosis	NDA Submitted, approval expected by mid-2009
Serdolect®, sertindole	5-H2 antagonist, 5-HT6 antagonist, D2 antagonist, afects alpha-1-adrenoceptor	Lundbeck	Psychosis	NDA Submitted (approved in EU)
Bifeprunox (DU-127090)	Partial agonist at dopamine D2 and serotonin 5-HT1A receptors	Solvay, Wyeth	Psychosis	Phase III (resubmission planned for 2009)
Corlux ® (AKA mifepristone or RU-486)	Glucocorticoid receptor type II (GRII) antagonist, progesterone receptor antagonist	Corcept	Psychosis, depression	Phase III
Pardoprunox, SLV 308	D2 partial agonist, 5-HT1A agonist	Solvay	Psychosis, Parkinson's disease	Phase III
LIC477D (licarbazepine)	Voltage-gated sodium channel inhibitor	Novartis	Psychosis	Phase III
Pimavanserin, ACP-103	Serotonin 5-HT2A receptor inverse agonist, dopamine D2/D3 receptor partial agonist, acetylcholine M1 receptor agonist	Acadia	Antipsychotic-induced side effects, Parkinson's disease psychosis	Phase III
ORG 34517/34850	Glucocorticoid receptor type II (GRII) antagonist	Schering-Plough	Depression, psychosis	Phase II
ORG 24448	AMPA modulator	Schering-Plough/Cortex	Psychosis	Phase II
Lurasidone (SM 13496)	D2, 5-HT2A antagonist	Merck, Dainippon Sumitomo	Psychosis	Phase II
RG2417 (triacetyluridine)	Prodrug of uridine	Repligen	Bipolar disorder	Phase II
Lonasen (blonanserin)	D2, 5-HT2A antagonist	Dainippon Sumitomo	Psychosis	Phase II
R1678	mGluR modulator	Roche	Psychosis	Phase II
LY2140023	Prodrug for an mGluR2/3 agonist	Eli Lilly	Psychosis	Phase II
Mirapex ® (pramipexole)	Dopamine D2, D3 receptor agonist	Boehringer-Ingelheim	Bipolar Disorder	Phase II
Lu-31-130	D1 antagonist, D2 antagonist, 5-HT2A antagonist	Lundbeck	Psychosis	Phase II
Caripazine, RGH-188	D2, D3 antagonist	Forest Labs	Psychosis	Phase II
Talnetant (SB-223412)	NK-3 antagonist	GSK	Psychosis, IBS, overactive bladder	Phase II
AVE1625	CB1 antagonist	Sanofi-Aventis	Psychosis	Phase II
GW742457	5-HT6 antagonist	GSK	Psychosis, Alzheimer's	Phase II
vabicaserin (SCA-136)	5-HT2C agonist	Wyeth	Schizophrenia	Phase II
P-101	Alpha-2-adrenoceptor antagonist	Potomac Pharma	Schizophrenia	Phase II
ORG 25935	GLYT1 (glycine transporter) inhibitor	Schering-Plough	Psychosis	Phase II
RG1068, secretin	Endogenous pancreatic hormone	Repligen	Psychosis, autism, anxiety	Phase II
ADX63365	MGluR agonist	Merck	Psychosis	Phase II
BL-1020	GABA-A agonist	BioLineRx	Psychosis	Phase II
TS-032	5-HT2A antagonist	Pfizer	Psychosis	Phase II
PF-217830	D3 antagonist	Pfizer	Psychosis	Phase II
PF-2545920	D3 antagonist	Pfizer	Psychosis	Phase II
SLV 313	5-HT2A antagonist	Solvay	Psychosis	Phase II
ABT-089	Nicotinic acetylcholine receptor agonist	Abbott Laboratories	Psychosis, ADHD	Phase I
GW773812	D2, 5-HT antagonist	GSK	Psychosis	Phase I
SSR 103800	GLYT1 (Type 1 glycine transporter) inhibitor	Sanofi-Aventis	Psychosis	Phase I
TC-1827	Selective alpha4beta2 nicotinic acetylcholine receptor agonist	Targacept	Cognitive impairment associated with schizophrenia	Phase I
JNJ-17305600	GLYT1 inhibitor	Johnson & Johnson	Psychosis	Phase I
XY 2401	Glycine site specific NMDA modulator	Xytis	Psychosis	Phase I
PNU 170413	D3 antagonist	Pfizer	Psychosis	Phase I
RGH-188	D2, D3 antagonist	Forrest	Psychosis	Phase I

Read more about Depression and Anxiety  Click here

REFERENCES:

1.      YK Wing, Recent advances in the management of depression and Psychopharmacology , HKMJ 2000;6:85-92

2.      Sanjay J Mathew, Husseini K Manji and Dennis S Charney ,Novel Drugs and Therapeutic Targets for Severe Mood Disorders;  Neuropsychopharmacology (2008), 1–13.

3.      JOHANNE ROSE L.AC. A;  Natural Approach to Depression , CLINICAL NUTRITION INSIGHTS Vol.6, No. 4

4.      Joseph A. Lieberman III, History of the Use of Antidepressants in Primary Care  Companion,  J Clin Psychiatry 2003;5[suppl 7]:6–10

5.      Madhukar H Trivedi, MD and Ella J Daly, MB, MRC ; Psych Treatment Strategies and Tactics for Treatment-resistant Depression, © T O U C H B R I E F I N G S 2 0 0 7.

6.      A report byThe British Psychological Society ;Division of Clinical psychology recent  advances in understanding mentalillness and psychotic experiences

By: Krishna kumar gokavarapu

BITS Pilani (M.Pharm)